Innovative approaches in CNS clinical drug development: Quantitative systems pharmacology.
作者： Clémence Lacroix , Thomas Soeiro , Marguerite Le Marois , Romain Guilhaumou , Catherine Cassé-Perrot
DOI: 10.1016/J.THERAP.2020.12.007
关键词:
摘要: Summary Clinical trials involving brain disorders are notoriously difficult to set up and run. Innovative ways develop effective prevention treatment strategies for central nervous system (CNS) diseases urgently needed. New approaches that likely renew or at least modify the paradigms used so far have been recently proposed. Quantitative systems pharmacology (QSP) uses mathematical computerized models characterize biological systems, disease processes CNS drug pharmacology. Integrated experimental medicine should increase probability predictability of success while controlling clinical costs. Finally, societal perspective patient empowerment also offer additional demonstrate benefit a new drug in field.
sci-hub.st 参考文章(55)
Keith A Wesnes, None, The value of assessing cognitive function in drug development. Dialogues in clinical neuroscience. ,vol. 2, pp. 183- 202 ,(2000)
Claire Lafay-Chebassier, François Chavant, Sylvie Favrelière, Véronique Pizzoglio, Marie-Christine Pérault-Pochat, Drug-induced Depression: a Case/Non Case Study in the French Pharmacovigilance Database Therapie. ,vol. 70, pp. 425- 432 ,(2015) , 10.2515/THERAPIE/2015026
Lori A. Knackstedt, Roberto I. Melendez, Peter W. Kalivas, Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine Seeking Biological Psychiatry. ,vol. 67, pp. 81- 84 ,(2010) , 10.1016/J.BIOPSYCH.2009.07.018
Elizabeth C. M. de Lange, Paulien G. M. Ravenstijn, Dorien Groenendaal, Tamara J. van Steeg, Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling Aaps Journal. ,vol. 7, ,(2005) , 10.1208/AAPSJ070354
Maryse Lapeyre-Mestre, Mathilde Dupui, Drug Abuse Monitoring: Which Pharmacoepidemiological Resources at the European Level? Therapie. ,vol. 70, pp. 157- 165 ,(2015) , 10.2515/THERAPIE/2015010
Olivier Blin, Ceri H Davies, Bai Lu, Clinical innovation for neurodegenerative diseases Clinical investigation. ,vol. 2, pp. 663- 665 ,(2012) , 10.4155/CLI.12.65
Antonello Caruso, Ruben Alvarez-Sánchez, Alexander Hillebrecht, Agnès Poirier, Franz Schuler, Thierry Lavé, Christoph Funk, Sara Belli, PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation Biochemical Pharmacology. ,vol. 85, pp. 1684- 1699 ,(2013) , 10.1016/J.BCP.2013.02.021
Zhijun Chen, Ying He, Zaijie Jim Wang, The beta-lactam antibiotic, ceftriaxone, inhibits the development of opioid-induced hyperalgesia in mice. Neuroscience Letters. ,vol. 509, pp. 69- 71 ,(2012) , 10.1016/J.NEULET.2011.12.029
Fabio Broccatelli, Caroline A. Larregieu, Gabriele Cruciani, Tudor I. Oprea, Leslie Z. Benet, Improving the prediction of the brain disposition for orally administered drugs using BDDCS Advanced Drug Delivery Reviews. ,vol. 64, pp. 95- 109 ,(2012) , 10.1016/J.ADDR.2011.12.008
Patrick Vlieghe, Michel Khrestchatisky, Peptide-based vectors for blood–brain barrier targeting and delivery of drugs to the central nervous system Therapeutic Delivery. ,vol. 1, pp. 489- 494 ,(2010) , 10.4155/TDE.10.44